NCT00269919View on ClinicalTrials.gov

An Efficacy and Safety Study of Long-Term Risperidone Microspheres in Participants With Schizophrenia

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions
SchizophreniaSchizoaffective Disorder
Interventions
DRUG

Risperidone Long-Acting Injectable (RLAI)

The RLAI 25 mg or 37.5 mg or 50 mg will be administered intramuscularly depending on Investigator's discretion every 2 weeks for 2 years.

Trial Locations (1)

Unknown

Seoul

All Listed Sponsors
lead

Janssen Korea, Ltd., Korea

INDUSTRY

NCT00269919 - An Efficacy and Safety Study of Long-Term Risperidone Microspheres in Participants With Schizophrenia | Biotech Hunter | Biotech Hunter